Adjuvant chemotherapy was discussed with 334 women (51.9%) and about half of these women (169 of 334, 50.6%) opted to receive chemotherapy, with the majority (153 of 169, 90.5%) completing the recommended regimen; 71 of these women had HER2-positive tumours and also received trastuzumab. The gene discussed is ERBB2; the disease is neoplasm.